AKERS LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Akers Biosciences, Inc. To Contact The Firm

Specifically, on May 21, 2018, Akers revealed both that it would delay filing its Form 10-Q with the SEC for the quarter ended March 31, 2018 and that it would continue reviewing the "characterization of certain revenue recognition items . . . now include[ing] certain transactions in previous quarters."

After the announcement, Aker's share price fell from $0.657 per share on May 21, 2018 to a closing price of $0.599 on May 22, 2018—a $0.058 or 8.82% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Aker's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View original content with multimedia:http://www.prnewswire.com/news-releases/akers-lead-plaintiff-deadline-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-exceeding-50-000-in-akers-biosciences-inc-to-contact-the-firm-300691939.html

SOURCE Faruqi & Faruqi, LLP